Responsibility for Development Costs. Development Costs for Combination Regimens Including BLU-554. Blueprint will reimburse CStone for [***] of all [***]expenses incurred by or on behalf of CStone in connection with the BLU-554/CStone Checkpoint Combination POC Trial, to the extent incurred in accordance with the BLU-554/CStone Checkpoint Combination POC Budget. Unless otherwise agreed by the Parties in writing, Blueprint will not be responsible for any costs and expenses incurred by or on behalf of CStone in connection with the BLU-554/CStone Checkpoint Combination POC Trial that exceed [***]. CStone will reimburse Blueprint for [***] of all [***] expenses incurred by or on behalf of Blueprint in connection with the BLU-554/Other Checkpoint Combination POC Trial (if conducted) (including the costs of supply of any antibody that binds to, targets, or otherwise recognizes [***] PD-L1 included in a BLU-554/Other Checkpoint Combination)[***]. Blueprint will be responsible for all costs and expenses incurred [***]. Each Party will invoice the other Party quarterly for the foregoing costs incurred by or on behalf of such Party in such Calendar Quarter, and the other Party will pay the undisputed invoiced amounts within [***] after the date of any such invoice.
Responsibility for Development Costs. Subject to adjustment pursuant to Section 3.3(d), the Parties shall share any and all Development Costs throughout the Territory with Novartis being responsible for sixty-two percent (62%) of all Development Costs and Company being responsible for thirty-eight percent (38%) of all Development Costs for each Collaboration Molecule, each Collaboration Product and all Early Research (collectively, such percentages for sharing Development Costs, the “Development Cost Sharing Percentages”). The calculation of the Development Cost Sharing Percentages is set forth in Exhibit 3.3(d).
Responsibility for Development Costs. Schering shall be responsible for all costs and expenses related to its Development of Schering Viral Products.
Responsibility for Development Costs. Throughout the Term of this Agreement, Takeda shall bear eighty percent (80%) and Amylin shall bear twenty percent (20%) of all U.S. Development Costs, except in the case of U.S. Development Costs of any Regulatory Approval Clinical Trial that is a cardiovascular safety study that becomes required by the FDA and is not already included in the then-current Development Plan at the time it becomes required by the FDA (a “CV Safety Study”). With respect to any CV Safety Study, Takeda shall bear [***] percent ([***] %) and Amylin shall bear [***] percent ([***] %) of all such U.S. Development Costs; provided, however, if the U.S. Development Costs of such CV Safety Study exceed, or are anticipated to exceed, [***] Dollars (US $[***]):
(i) Takeda shall, upon Amylin’s written request, be obligated to pay all U.S. Development Costs that exceed [***] Dollars (US $[***]); and (ii) Amylin shall, within [***] following the database lock or earlier termination of the CV Safety Study (the “Database Lock Date”), reimburse Takeda an amount equal to [***] percent ([***] %) of such U.S. Development Costs that exceeded [***] Dollars (US $[***]), plus simple interest calculated at three-month LIBOR (the “Loan”). Amylin shall be required to pay at least [***] ([***] %) of the Loan upon each of the [***] anniversary of the Database Lock Date and the [***] anniversary of the Database Lock Date; provided, however, Takeda shall have the right to set-off, in any calendar year, against any payments due from Takeda to Amylin under this Agreement by the amount that Amylin is obligated to pay Takeda for reimbursement of the Loan during such calendar year. For the avoidance of doubt, Amylin may reimburse Takeda the full amount of the Loan prior to the due date with no prepayment penalty. Takeda shall bear one hundred percent (100%) of all Development Costs that are not U.S.
Responsibility for Development Costs. All Development Costs shall be the responsibility of and shall be paid directly by HPS.
Responsibility for Development Costs. 4.11.1 For clarity, and except as otherwise specified in any Development Budgets included in the Global Development Plan and subject to the terms and conditions hereof (including Section 4.1): (a) Xxxxxxx shall bear one hundred percent (100%) of the Development Costs incurred in connection with activities conducted by or on behalf of Xxxxxxx, its Affiliates and/or its sublicensees for the Initial Study and all studies other than any Ongoing Studies conducted under the Global Development Plan; (b) Achillion shall bear one hundred percent (100%) of the Development Costs incurred in connection with activities conducted by or on behalf of Achillion, its Affiliates and/or its sublicensees for all Ongoing Studies being wound down under the Global Development Plan; and (c) Xxxxxxx shall be responsible for all Development Costs for all Ongoing Studies being continued under the Global Development Plan.
4.11.2 Notwithstanding anything to the contrary herein, any license payments (including any fees, milestones, or royalties) due from Achillion to any Third Party under any Pre-Existing Licenses from Third Parties or any Additional Pre-Existing Third Party Agreements of Achillion on account of any Development of Licensed Product hereunder shall be a sole expense of Achillion, and not be deemed Development Costs allocable to any extent to Xxxxxxx hereunder.
Responsibility for Development Costs. Unless otherwise agreed by the Parties in writing, MERCK shall be responsible for funding one-hundred percent (100%) of the development costs incurred for all Products throughout the Territory, including any Development Costs that CARDIOME agrees to incur. MERCK shall not, however, be responsible for Development Costs incurred by CARDIOME except to the extent that such Development Costs are expressly included in a Development Plan and any budget which forms a part of such plan or otherwise reviewed and approved in writing, in advance, by MERCK, either through the PDT or otherwise. For clarity, CARDIOME will use Commercially Reasonable Efforts to complete the AVRO Trial and bear the costs of completing the AVRO Trial, and such costs will not be Development Costs hereunder.
Responsibility for Development Costs. Except as otherwise set forth herein, all Development Costs shall be the responsibility of and shall be paid directly by the Person that is responsible for the payment of such Development Costs under the Development Agreement (i.e., either CPHP or CPDC) (the “Applicable Payor”).
Responsibility for Development Costs. Responsibility for the funding of the payment of Development Costs shall be shared by the Members pro rata, on the basis of their respective Sharing Ratios.
Responsibility for Development Costs. The responsibilities of the Parties with respect to Development Costs through Lead Identification shall be as set forth in this Section 3.10. [*] will be responsible, on a Target-by-Target basis, for payment of [*] percent ([*] %) of the Development Costs incurred, in accordance with budgets therefore set forth in the Research Plan, during all stages of the Research Collaboration through Lead Identification. Subject to Section 4.8, CVT shall be responsible for all Development Costs following Lead Identification. If PTC exercises a Lead Optimization Opt-In Right or an IND Opt-In Right with respect to a particular Target under Section 4.8, then [*] will be responsible for payment of [*] percent ([*] %) of the Development Costs incurred, in accordance with budgets and plan therefor established pursuant to Section 4.8(a) or 4.8(b), as applicable, after such exercise through the completion of the applicable Clinical Proof-of-Concept Study. CVT shall provide to PTC good faith annual budgets and plans through the JMC, as set forth in Section 2.3(c). The Parties shall reconcile and pay for Development Costs as set forth in Section 5.3. Notwithstanding the foregoing, CVT shall not be responsible for any Development Costs with respect to Non-Collaboration Compounds incurred after such Non-Collaboration Compounds cease to be subject to the Research Collaboration under Sections 3.5, 3.6 and 3.7. [*] Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
